dc.contributor.author | Artunay, Özgür | |
dc.contributor.author | Yüzbaşıoğlu, Erdal | |
dc.contributor.author | Rasier, Rıfat | |
dc.contributor.author | Şengül, Alper | |
dc.contributor.author | Bahçecioğlu, Halil | |
dc.date.accessioned | 2014-12-29T07:44:50Z | |
dc.date.available | 2014-12-29T07:44:50Z | |
dc.date.issued | 2009 | |
dc.identifier.citation | Artunay O, Yuzbasioğlu E, Rasier R, Sengul A, Bahcecioglu H. Acute retinal arterial occlusion after intravenous administration of bevacizumab. BMJ Case Reports. 2009. doi:10.1136/bcr.01.2009.1478 | en_US |
dc.identifier.issn | 1757-790X | en_US |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3029805/ | en_US |
dc.identifier.uri | http://casereports.bmj.com/content/2009/bcr.01.2009.1478.long | en_US |
dc.identifier.uri | https://hdl.handle.net/11446/626 | en_US |
dc.description | İstanbul Bilim Üniversitesi, Tıp Fakültesi. | en_US |
dc.description.abstract | Retinal artery occlusions are usually the result of emboli, although non-embolic causes such as vasculitides, coagulopathies, and vasospasms resulting from migraines and inflammatory conditions do occur. Bevacizumab, a humanised monoclonal antibody, is designed to bind to and inhibit vascular endothelial growth factor (VEGF). VEGF is a protein that plays a critical role in tumour angiogenesis, the formation of new blood vessels to the tumour. The use of bevacizumab has spread worldwide, but the drug related adverse events associated with its use have been reported in a few retrospective reviews. We report on a previously unpublished case of retinal artery occlusion following the use of systemic bevacizumab. | en |
dc.language.iso | eng | en_US |
dc.publisher | http://group.bmj.com/ | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.title | Acute retinal arterial occlusion after intravenous administration of bevacizumab | en_US |
dc.type | article | en_US |
dc.relation.journal | BMJ Case Reports | en_US |
dc.department | DBÜ, Tıp Fakültesi | en_US |
dc.contributor.authorID | TR58689 | en_US |
dc.contributor.authorID | TR42222 | en_US |
dc.contributor.authorID | TR27545 | en_US |
dc.contributor.authorID | TR39806 | en_US |
dc.contributor.authorID | TR141057 | en_US |
dc.relation.publicationcategory | Belirsiz | en_US |